Global CRISPR gene editing market will reach $16,329.8 million by 2031, growing by 26.4% annually over 2021-2031, driven by the rising demand for better food and medical products, innovative advancement in gene therapy supported by the continued investments in healthcare, rising geriatric population and the increasing genomic and chronic diseases, and the development of rapid CRISPR-based POC tests amid COVID-19 pandemic.
Highlighted with 87 tables and 86 figures, this 180-page report 鈥淕lobal CRISPR Gene Editing 麻豆原创 2021-2031 by Offering (Products, Services), Application (Biomedical, Agriculture, Industrial, Others), End User (Pharmaceutical Companies, Biotechnology Companies, Academic Institutions & Research Centers, Others), and Region: Trend Forecast and Growth Opportunity鈥� is based on a comprehensive research of the entire global CRISPR gene editing market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2018-2021 and provides forecast from 2022 till 2031 with 2021 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
鈥� 麻豆原创 Structure
鈥� Growth Drivers
鈥� Restraints and Challenges
鈥� Emerging Product Trends & 麻豆原创 Opportunities
鈥� Porter鈥檚 Fiver Forces
The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify global CRISPR gene editing market in every aspect of the classification from perspectives of Offering, Application, End User, and Region.
Based on Offering, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
鈥� CRISPR Products
o Kits & Enzymes
飩� Vector-Based Cas9
飩� DNA-Free Cas9
o Databases & Libraries
o Design Tools
o Antibodies
o CRISPR Plasmid & Vector
o Other Products
鈥� CRISPR Services
o gRNA Design & Vector Construction
o Cell Line Engineering
o Microbial Gene Editing
o DNA Synthesis
o Other Services
Based on Application, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
鈥� Biomedical Research & Therapy
o Gene Therapy
o Drug Discovery
o Diagnostics
o Other Biomedical Applications
鈥� Agriculture
鈥� Industrial Use
鈥� Other Applications
By End User, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
鈥� Pharmaceutical Companies
鈥� Biotechnology Companies
鈥� Academic Institutions & Research Centers
鈥� Other End Users
Geographically, the following regions together with the listed national/local markets are fully investigated:
鈥� North America (U.S., Canada, and Mexico)
鈥� Europe (Germany, UK, France, Spain, Italy, Netherlands, Rest of Europe; Rest of Europe is further segmented into Switzerland, Russia, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
鈥� APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
鈥� South America (Brazil, Chile, Argentina, Rest of South America)
鈥� MEA (UAE, Saudi Arabia, South Africa, Other Nations)
For each aforementioned region and country, detailed analysis and data for annual revenue ($ mn) are available for 2021-2031. The breakdown of all regional markets by country and split of key national markets by Offering, Application, and End User, over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Selected Key Players:
Abcam, Inc.
Agilent Technologies, Inc.
Applied StemCell, Inc.
Caribou Biosciences, Inc.
Cellecta, Inc.
CRISPR Therapeutics AG
Editas Medicine, Inc.
GeneCopoeia, Inc.
GeneScript Biotech Corporation
Horizon Discovery Group PLC
Integrated DNA Technologies, Inc.
Intellia Therapeutics Inc.
Lonza Group Ltd.
Merck KGaA
New England Biolabs, Inc.
Origene Technologies, Inc.
Rockland Immunochemicals, Inc.
Synthego Corporation
System Biosciences LLC
Takara Bio, Inc.
Thermo Fisher Scientific, Inc.
ToolGen, Inc.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
1 Introduction 9
1.1 Industry Definition and Research Scope 9
1.1.1 Industry Definition 9
1.1.2 Research Scope 11
1.2 Research Methodology 14
1.2.1 Overview of 麻豆原创 Research Methodology 14
1.2.2 麻豆原创 Assumption 15
1.2.3 Secondary Data 15
1.2.4 Primary Data 15
1.2.5 Data Filtration and Model Design 16
1.2.6 麻豆原创 Size/Share Estimation 17
1.2.7 Research Limitations 18
1.3 Executive Summary 19
2 麻豆原创 Overview and Dynamics 21
2.1 麻豆原创 Size and Forecast 21
2.1.1 Impact of COVID-19 on World Economy 24
2.1.2 Impact of COVID-19 on the 麻豆原创 26
2.2 Major Growth Drivers 28
2.3 麻豆原创 Restraints and Challenges 37
2.4 Emerging Opportunities and 麻豆原创 Trends 40
2.5 Porter鈥檚 Fiver Forces Analysis 44
3 Segmentation of Global 麻豆原创 by Offering 48
3.1 麻豆原创 Overview by Offering 48
3.2 CRISPR Products 50
3.2.1 Kits & Enzymes 52
3.2.2 Databases & Libraries 53
3.2.3 Design Tools 54
3.2.4 Antibodies 55
3.2.5 CRISPR Plasmid & Vector 56
3.2.6 Other Products 57
3.3 CRISPR Services 58
3.3.1 gRNA Design & Vector Construction 60
3.3.2 Cell Line Engineering 61
3.3.3 Microbial Gene Editing 62
3.3.4 DNA Synthesis 63
3.3.5 Other Services 64
4 Segmentation of Global 麻豆原创 by Application 65
4.1 麻豆原创 Overview by Application 65
4.2 Biomedical Research & Therapy 67
4.2.1 Gene Therapy 69
4.2.2 Drug Discovery 70
4.2.3 Diagnostics 71
4.2.4 Other Biomedical Applications 72
4.3 Agriculture 73
4.4 Industrial Use 74
4.5 Other Applications 75
5 Segmentation of Global 麻豆原创 by End User 76
5.1 麻豆原创 Overview by End User 76
5.2 Pharmaceutical Companies 78
5.3 Biotechnology Companies 79
5.4 Academic Institutions & Research Centers 80
5.5 Other End Users 81
6 Segmentation of Global 麻豆原创 by Region 82
6.1 Geographic 麻豆原创 Overview 2021-2031 82
6.2 North America 麻豆原创 2021-2031 by Country 86
6.2.1 Overview of North America 麻豆原创 86
6.2.2 U.S. 90
6.2.3 Canada 93
6.2.4 Mexico 95
6.3 European 麻豆原创 2021-2031 by Country 97
6.3.1 Overview of European 麻豆原创 97
6.3.2 Germany 101
6.3.3 U.K. 103
6.3.4 France 105
6.3.5 Spain 107
6.3.6 Italy 109
6.3.7 Netherlands 111
6.3.8 Rest of European 麻豆原创 113
6.4 Asia-Pacific 麻豆原创 2021-2031 by Country 115
6.4.1 Overview of Asia-Pacific 麻豆原创 115
6.4.2 Japan 119
6.4.3 China 122
6.4.4 Australia 124
6.4.5 India 126
6.4.6 South Korea 128
6.4.7 Rest of APAC Region 130
6.5 South America 麻豆原创 2021-2031 by Country 132
6.5.1 Argentina 135
6.5.2 Brazil 137
6.5.3 Chile 139
6.5.4 Rest of South America 麻豆原创 141
6.6 MEA 麻豆原创 2021-2031 by Country 142
6.6.1 UAE 145
6.6.2 Saudi Arabia 147
6.6.3 South Africa 149
6.6.4 Other National 麻豆原创s 151
7 Competitive Landscape 152
7.1 Overview of Key Vendors 152
7.2 New Product Launch, Partnership, Investment, and M&A 156
7.3 Company Profiles 157
Abcam, Inc. 157
Agilent Technologies, Inc. 159
Applied StemCell, Inc. 160
Caribou Biosciences, Inc. 161
Cellecta, Inc. 162
CRISPR Therapeutics AG 163
Editas Medicine, Inc. 164
GeneCopoeia, Inc. 165
GeneScript Biotech Corporation 166
Horizon Discovery Group PLC 167
Integrated DNA Technologies, Inc. 168
Intellia Therapeutics Inc. 169
Lonza Group Ltd. 170
Merck KGaA 171
New England Biolabs, Inc. 172
Origene Technologies, Inc. 173
Rockland Immunochemicals, Inc. 174
Synthego Corporation 175
System Biosciences LLC 176
Takara Bio, Inc. 177
Thermo Fisher Scientific, Inc. 178
ToolGen, Inc. 179
RELATED REPORTS 180
Selected Key Players:
Abcam, Inc.
Agilent Technologies, Inc.
Applied StemCell, Inc.
Caribou Biosciences, Inc.
Cellecta, Inc.
CRISPR Therapeutics AG
Editas Medicine, Inc.
GeneCopoeia, Inc.
GeneScript Biotech Corporation
Horizon Discovery Group PLC
Integrated DNA Technologies, Inc.
Intellia Therapeutics Inc.
Lonza Group Ltd.
Merck KGaA
New England Biolabs, Inc.
Origene Technologies, Inc.
Rockland Immunochemicals, Inc.
Synthego Corporation
System Biosciences LLC
Takara Bio, Inc.
Thermo Fisher Scientific, Inc.
ToolGen, Inc.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
听
听
*If Applicable.
